Clinical Highlights of Retatrutide Study: 48-week, double-blind, placebo-controlled Phase 2 trial Results: ~22.8% weight loss (8 mg dose), ~28.2% weight loss (12 mg dose) ~0.9% HbA1c reduction Significant improvements in cardiometabolic risk factors Safety & Tolerability Most common side effects: nausea, vomiting, diarrhea, abdominal discomfort, constipation typically mild to moderate and dose-dependent
On this page, well answer this question in further depth, qualifications that matter most in dangerous drug lawsuits, and much more
But our commitment doesn't end with whats inside the tub
The hypothalamic arcuate nucleus: a key site for mediating leptin's effects on glucose homeostasis and locomotor activity
While a promising approach, future work to address product stability and efficacy in larger eyes is needed for further development
Most treatments involve minimal discomfort